Novartis to seek US approval of siponimod for SPMS: industry news round up

Clinical trial announcements, orphan-drug designation and more: check out our round-up of the biggest news from the neuroscience and neurology industries this week. Our pick of the highlights include: Rimegepant successfully achieves primary endpoints in two Phase III trials for migraine Novartis to seek US approval of siponimod in patients with SPMS Constant Pharmaceuticals announces European patent issuance for TXA127 in stroke treatment GeneTx Biotherapeutics receives US FDA orphan-drug designation for Angelman syndrome Rimegepant successfully achieves primary endpoints in two Phase III trials for migraine Earlier this week, Biohaven Pharmaceutical Holding Company Ltd (CT, USA) announced successful achievement of both...